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Abstract
Neisseria meningitidis is a major cause of bacterial meningitis and sepsis worldwide. Lipopolysaccharide (LPS), a major
component of the Gram-negative bacterial outer membrane, is sensed by mammalian cells through Toll-like receptor 4
(TLR4), resulting in activation of proinflammatory cytokine pathways. TLR4 recognizes the lipid A moiety of the LPS
molecule, and the chemical composition of the lipid A determines how well it is recognized by TLR4. N. meningitidis has
been reported to produce lipid A with six acyl chains, the optimal number for TLR4 recognition. Indeed, meningococcal
sepsis is generally seen as the prototypical endotoxin-mediated disease. In the present study, we screened meningococcal
disease isolates from 464 patients for their ability to induce cytokine production in vitro. We found that around 9% of them
were dramatically less potent than wild-type strains. Analysis of the lipid A of several of the low-activity strains by mass
spectrometry revealed they were penta-acylated, suggesting a mutation in the lpxL1 or lpxL2 genes required for addition of
secondary acyl chains. Sequencing of these genes showed that all the low activity strains had mutations that inactivated the
lpxL1 gene. In order to see whether lpxL1 mutants might give a different clinical picture, we investigated the clinical
correlate of these mutations in a prospective nationwide observational cohort study of adults with meningococcal
meningitis. Patients infected with an lpxL1 mutant presented significantly less frequently with rash and had higher
thrombocyte counts, consistent with reduced cytokine induction and less activation of tissue-factor mediated
coagulopathy. In conclusion, here we report for the first time that a surprisingly large fraction of meningococcal clinical
isolates have LPS with underacylated lipid A due to mutations in the lpxL1 gene. The resulting low-activity LPS may have an
important role in virulence by aiding the bacteria to evade the innate immune system. Our results provide the first example
of a specific mutation in N. meningitidis that can be correlated with the clinical course of meningococcal disease.
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Introduction
Neisseria meningitidis is a major cause of bacterial meningitis and
sepsis worldwide [1]. While it is a frequent commensal of the
human upper respiratory tract, in some individuals the bacterium
spreads to the bloodstream causing meningitis and/or sepsis,
serious conditions with high morbidity and mortality. As in all
Gram-negative bacteria, lipopolysaccharide (LPS) is a major
component of the outer membrane of N. meningitidis. It is now
well established that LPS is sensed by mammalian cells through
Toll-like receptor 4 (TLR4), in combination with coreceptors MD-
2 and CD14 [2]. Activation of this complex leads to recruitment of
the adapters MyD88, Mal, TRIF, and TRAM to the cytoplasmic
domain of TLR4 [3]. These adapters initiate signal transduction
pathways that lead to induction of innate immunity. These
pathways are classified in a so called ‘‘MyD88-dependent’’
pathway involving MyD88 and Mal, and a ‘‘MyD88-indepen-
dent’’ pathway involving TRIF and TRAM. Hallmarks of
MyD88-dependent and MyD88-independent signaling are induc-
tion of pro-inflammatory cytokines and type I IFN respectively.
While the response to LPS can be beneficial to the host by
containing a beginning infection, it can also be detrimental when
excessive stimulation occurs through growth of large numbers of
bacteria in the bloodstream as happens during sepsis [2,4,5].
TLR4 recognizes the lipid A moiety of the LPS molecule [2].
The chemical composition of the lipid A determines how well it is
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activity of the LPS. N. meningitidis has been reported to produce
lipid A with six acyl chains, the optimal number for TLR4
recognition [6]. Indeed purified LPS of this bacterium is highly
active and plasma concentrations of LPS in patients with
meningococcal disease correlate strongly with mortality risk [7].
LPS is also important in the activation of the coagulation system
through upregulation of tissue factor. Excessive activation of the
coagulation system can lead to disseminated intravascular
coagulation (DIC), the most feared complication of invasive
meningococcal disease [1]. DIC is clinically characterized by
hypotension, petechial rash, and depletion of thrombocytes and
coagulation factors.
Uniquely among Gram-negative bacteria, N. meningitidis cangrow
without LPS, as was shown by us when we constructed a mutant
with an inactivated lpxA gene, required for the first step in LPS
biosynthesis [8]. In addition, we have previously shown that
insertional inactivation of the lpxL1 or lpxL2 genes required for
addition ofsecondary acyl chains leads to reduced biological activity
of meningococcal LPS [9,10]. The possibility that such mutations
might also occur naturally was suggested to us by a report showing
that the group Y strain HF13 was defective in signaling through the
MyD88-independent pathway and TLR4 [11].
Here we report that strain HF13 has penta-acylated lipid A due
to a mutation in its lpxL1 gene. Screening of a selection of clinical
isolates revealed lpxL1 mutations in approximately 13% of
meningococcal disease isolates of all major serogroups and clonal
complexes. Several different kinds of mutations were found. We
also found evidence for on-and-off switching of lpxL1 in vivo in
humans. Importantly, patients with meningococcal meningitis that
were infected with an lpxL1 mutant strain had less severe systemic
inflammation and reduced coagulopathy.
Results
Strain HF13 is a natural lpxL1 mutant
Mogensen et al. demonstrated that the serogroup Y strain HF13
is defective in TLR4 activation and initiation of MyD88-
independent signaling [11]. Reduced biological activity of
meningococcal LPS is associated with altered lipid A structure
[9,10]. Therefore, the lipid A structure of strain HF13 was assessed
by mass spectrometry (Figure 1A). The spectrum shows major
peaks that correspond with lipid A with only five acyl chains. One
of the two secondary C12 acyl chains is absent, but the spectrum is
not conclusive on which one, since the C12 acyl chains have the
same mass. This result implies that in strain HF13 either lpxL1 or
lpxL2 is inactive, as we previously found that the addition of the
secondary C12 acyl chains to lipid A requires active lpxL1 and
lpxL2 [9]. Sequence analyses of both genes showed a normal lpxL2
sequence, but the lpxL1 sequence contained one adenosine
deletion in a poly adenosine tract, leading to a frameshift and a
premature stop of the translated protein (Figure 2, Table 1).
The inactivated lpxL1 gene in strain HF13 results in a penta-
acylated lipid A lacking the secondary acyl chain at the 29-position
in lipid A, while N. meningitidis typically has a hexa-acylated lipid A
(Figure 1B). These results provide an explanation for the inability
of strain HF13 to activate TLR4 and to initiate MyD88-
independent signaling.
Mutations in lpxL1 are present in several serogroups and
clonal complexes
To evaluate the distribution of lpxL1 mutations among
meningococcal isolates from patients, we initially screened a panel
of 56 serogroup Y meningococcal isolates for their capacity to
induce the MyD88-independent cytokine IP-10 in the mouse
macrophage cell line J774A.1 (Figure S1). As controls, strain H44/
76 and HF13 were included. Of 56 serogroup Y isolates, eight
strains induced like HF13 little or no IP-10. Sequence analyses of
lpxL1 of these isolates revealed that they all had mutations in lpxL1,
resulting in an inactive gene. Five strains had one adenosine
deletion in a poly A tract just like strain HF13 (type V mutation,
Figure 2, Table 1), two strains had a deletion of ten nucleotides
(type VI mutation), and one strain had an insertion of the insertion
element IS1301 (Type I mutation).
These results prompted us to investigate the distribution of lpxL1
mutations among meningococci of the major serogroups and
clonal complexes. Previously, we have shown that at higher
dilutions an lpxL1 mutant induces less pro-inflammatory cytokines
than wild-type N. meningitidis [9,10]. To identify meningococcal
isolates with mutations in lpxL1, isolates were tested on their
capacity to induce IL-6 in the human monocytic cell line Mono
Mac 6 (MM6). Of 114 isolates, representing all major serogroups
and clonal complexes, 13 were found to induce low amounts of IL-
6 (Figure S2). Sequence analyses of lpxL1 showed that 12 isolates
had a mutation in lpxL1, rendering the gene inactive (Figure 2,
Table 1). Of these strains, 10 had an insertion or deletion in a
polyadenosine or polyguanosine tract (type III, IV and V
mutations); six of these had the same mutation as found in the
majority of mutant serogroup Y strains. One strain had a type VI
mutation, like in the two aforementioned serogroup Y strains. One
strain had a deletion of the C-terminal part of the gene (type VII
mutation). The remaining strain (2020799) had apparently no
mutation in lpxL1 that would lead to its inactivation. However,
closer examination of its putative amino acid sequence showed
that one amino acid was altered at a position conserved in all
known lpxL1 homologues. Therefore, the LpxL1 protein of this
strain is probably nonfunctional. Indeed, we confirmed that strain
2020799 had penta-acylated lipid A by mass spectrometry (data
not shown). As a control, also lpxL1 of 34 strains that induced a
normal level of IL-6 was sequenced. As expected, these strains had
no mutations in lpxL1 (data not shown). Together, seven unique
lpxL1 mutations were found among this panel of different
Author Summary
Neisseria meningitidis is a Gram-negative bacterium that
can cause the life-threatening diseases meningitis and
sepsis. Most of the symptoms seen in these diseases are
the result of excessive stimulation of the immune system
by lipopolysaccharide (LPS), a major component of the
outer membrane of Gram-negative bacteria. The structure
of the membrane-anchoring part of LPS, named lipid A,
determines how well it is recognized by TLR4, the receptor
which triggers this response. N. meningitidis has been
shown previously to make a highly active form of LPS with
six fatty acyl chains in its lipid A moiety. We now show that
a surprisingly large fraction of meningococcal patient
isolates have a mutation in one of their lipid A biosynthesis
genes, which makes their LPS underacylated and which
strongly decreases their capability to activate the immune
system. Presumably, selection of these mutants is promot-
ed because the reduced activation aids the bacteria to
escape elimination within the human host. We further
demonstrate that meningitis patients infected with these
LPS mutants have less severe symptoms than patients
infected with wild-type strains. This is the first instance
where a specific bacterial mutation can be correlated with
the clinical course of meningococcal disease.
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inactivation of lpxL1 must have occurred multiple times indepen-
dently. The results show that lpxL1 mutations are not associated
with serogroup or clonal complexes and occur also among the
serogroup B and C strains, which are prevalent among isolates
from patients with meningococcal disease in Europe.
Screening of lpxL1 mutations in a panel of multiple
isolates per patient
Most of the identified lpxL1 mutations were in nucleotide repeats
of adenosines and guanosines, the type III, IV and V mutations
(Figure 2, Table 1). These sequences are prone to cause slippage of
the DNA polymerase during DNA replication, leading to reversible
frameshift mutations. This slipped-strand mispairing is the most
common mechanism of translational phase variation, the process of
random and reversible on-and-off switching of a gene. Phase
variation creates a phenotypically diverse population, allowing the
bacterium to adapt to different microenvironments within the
human host. To investigate whether N. meningitidis can switch lpxL1
on-and-off we screened a panel of strains obtained from different
anatomical locations within individual patients: isolates from the
blood and/or cerebrospinal fluid (CSF) as well as from the throat
and/or nose of 40 patients were used. The MM6 cell line was
stimulated with these strains and IL-6 production was measured
with ELISA. Three strains induced low levels of IL-6 compared to
wild-type N. meningitidis (Figure S3). These isolates were from three
different patients. Two strains were isolated from the cerebrospinal
fluid and one strain was isolated from the throat. The other isolates
of these patients induced normal levels of IL-6. The lpxL1 genes of
all isolates of these three patients were sequenced and found to be
mutated in the isolates that induced low IL-6, but not in the isolates
that induced normal IL-6 (Figure 2, Table 1). Two strains had a
type IV mutation, which potentially is reversible. The third strain
had a point mutation leading to substitution of a conserved amino
acid. These results suggest that in the host the expression status of
lpxL1 of meningococci is subject to phase variation.
Figure 1. Strain HF13 is an lpxL1 mutant. (A) Mass spectrum of HF13 lipid A. The highest peak (1653.6) corresponds to penta-acylated lipid A
with two phosphate groups and one phosphoethanolamine (PEA); the second peak (1530.4) corresponds to penta-acytlated lipid A with two
phosphate groups without PEA. (B) Depiction of N. meningitidis wild-type lipid A. The acyl chain that is added by LpxL1 is indicated.
doi:10.1371/journal.ppat.1000396.g001
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a TLR4–dependent manner
The identified lpxL1 mutations occurred in strains of widely
varying genetic background, and it is therefore conceivable that
other factors besides altered LPS contribute to their reduced
cytokine induction. To investigate this, titrations of four of the
spontaneous lpxL1 mutants were compared in their capacity to
induce cytokines in MM6 cells with titrations of our previously
constructed lpxL1 knockout mutant and its parent strain H44/76,
as well as the completely LPS-deficient strain pLAK33 (Figure 3).
Clearly, the LPS-deficient strain pLAK33 is much less potent in
inducing IL-6 than the wild-type strain H44/76. IL-6 induction by
the constructed lpxL1 mutant is similar to that by pLAK33 and the
four lpxL1 mutants isolated from patients.
To demonstrate that the lpxL1 mutants induced less cytokines
than wild-type strains because their LPS is less well recognized by
the LPS receptor complex, titrations of a similar panel of strains
was used to stimulate HEK293 cells transfected with human
TLR4, MD-2, and CD14. Activation of the receptor complex was
assessed by measuring IL-8 production (Figure 4). Wild-type strain
H44/76 was much more efficient in TLR4 activation than the
mutants. All lpxL1 mutants, either constructed or isolated from
patients, showed a similar decrease in IL-8 induction, while the
LPS-deficient pLAK33 cells were even less active. Together, these
results demonstrate that the lpxL1 mutants activate human TLR4
less efficiently, and this is the sole reason for their reduced
biological activity.
We have shown that lpxL1 mutants induce less cytokines in
human and murine cell lines. However, these in vitro models do not
necessarily represent the situation in vivo and do not take into
account the genetic diversity of the human population. To mimic a
systemic meningococcal infection more closely, also human
peripheral blood mononuclear cells (PBMCs) of several donors
were stimulated with titrations of a selection of N. meningitidis
strains. After stimulation, concentrations of IL-6, TNF-a, and IL-
1b were determined in the supernatant (Figure 5). These pro-
inflammatory cytokines are known to mediate the toxic effects of
LPS [2]. In all donors, wild-type strain H44/76 induced much
more IL-6, TNF-a, and IL-1b than the mutants. Overall, the
constructed and spontaneous lpxL1 mutants showed a similar
reduction in cytokine induction.
Meningitis patients infected with lpxL1 mutant
meningococci have reduced inflammation and
coagulopathy
We next explored whether infection with lpxL1-mutant
meningococcal strains was associated with a particular clinical
phenotype. The meningococcal isolates from 254 patients from a
prospective nationwide observational cohort study of 696 adults
with community-acquired bacterial meningitis in the Netherlands
(period, 1998–2002) [12,13] were analyzed for their ability to
induce IL-6. Of the 254 isolates, 172 (68%) were of serogroup B,
78 (31%) of serogroup C, 3 (1%) of serogroup Y, and one (,1%) of
serogroup W135. Multilocus sequence typing showed 91 unique
sequence types. The most prevalent clonal complexes were cc41/
44 (41%), cc11 (24%), and cc32 (16%) [13].
MM6 cells were stimulated with these strains and IL-6
induction was assessed (Figure S4). The isolates of 17 patients
(7%) showed a decreased IL-6 induction and sequencing revealed
mutations in lpxL1 in all but one (Figure 2, Table 1). Twelve
isolates had a type III, IV or V mutation. Three strains had a point
mutation leading to substitution of an essential amino acid, and
Figure 2. Presentation of all lpxL1 mutations. The lpxL1 gene sequence of strain MC58 is shown including the different types of mutations and
their positions in the gene found among isolates from patients. Each type of mutation is indicated with a different color. An ‘_’ indicates a nucleotide
that is deleted in the mutant strain, pink indicates an insertion element (type I and II mutations), yellow indicates a deletion of a guanine in a stretch
of five guanines (type III mutation), green indicates a deletion of an adenosine in a stretch of five adenosines (type IV mutation), light blue indicates a
deletion of an adenosine in a stretch of seven adenosines (type V mutation), dark blue indicates an insertion of an adenosine in a stretch of seven
adenosines (type V mutation), and the sequences that are highlighted in red or gray are deleted in the mutant strain (type VI and VII mutations
respectively).
doi:10.1371/journal.ppat.1000396.g002
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Strain no. Isolated from serogroup ST Clonal complex Type of mutation in lpxL1
a
lpxL1 mutants among 56 serogroup Y isolates
HF13 Nd
b Yn d n d V
2011169 blood Y 23 23 V
2040760 blood Y 23 23 V
970455 blood Y nd nd V
2050913 joint puncture Y 2786 23 V
971523 CSF Y nd nd V
971886 CSF Y nd nd VI
982195 blood Y nd nd VI
2040608 CSF Y nd nd I
lpxL1 mutants among 114 isolates representing major serogroups and clonal complexes
2000569 blood X 750 750 V
2011833 blood C 3553 269 V
2041268 blood B 4926 35 V
2050093 blood B 461 461 V
2030162 blood C 337 41/44 V
2051372 blood B 461 461 V
2010151 blood C 461 461 IV
2021270 CSF C 461 461 III
2041396 CSF B 4930 18 III
2050806 CSF B 213 213 III
2071416 blood Y 23 23 VI
2020799
c CSF B 35 35 conserved amino acid change
2050392 CSF B 213 213 VII
lpxL1 mutants among multiple isolates from a single patient
Patient 94176
941761 I CSF C nd nd conserved amino acid change
941761 III Troat swab C nd nd wild-type
Patient 9707010
970710 I CSF C nd nd wild-type
970710 III nose swab C nd nd IV
Patient 971859
971859 I CSF C nd nd IV
971859 III Throat swab C nd nd wild-type
lpxL1 mutants among isolates from 254 patients in the prospective cohort study
2012202 CSF B 41 41/44 V
2020434 CSF C 11 11 V
991174 CSF C 11 11 V
990576 CSF B 571 41/44 V
991382 CSF B 191 41/44 V
2011833 CSF C 3553 269 V
991344 CSF B 42 41/44 III
2000607 CSF B 40 41/44 III
2000311 CSF B 461 461 III
991093 CSF B 5451 32 III
2020622 CSF B 5458 41/44 IV
990344 CSF B 5449 41/44 IV
2010640 CSF B 1474 41/44 conserved amino acid change
2011334 CSF C 11 11 II
2011764 CSF B 303 41/44 conserved amino acid change
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unable to identify a mutation in lpxL1 that could lead to gene
inactivation or inactive gene product. Further analyses with mass
spectrometry to determine the mass of its lipid A and silver
staining of a Tricine-SDS-PAGE gel to analyze the size and
quantity of its LPS, demonstrated that LPS was not detectable in
this strain (results not shown). The responsible mutation remains to
be identified. There were no overall differences in lpxL1 mutation
frequency between serogroups (P=0.85) and clonal complexes
(P=0.56).
Next, we correlated results of the mutation analysis with clinical
data (Table 2) [12,13]. Patients infected with lpxL1 mutant strains
tended to be younger (P=0.053) and to present less frequently
with fever (P=0.057). None of the patients infected with an lpxL1
mutant strain presented with hypotension and these patients had
correspondingly lower levels of serum creatinine. They were less
likely to present with rash compared with those infected with wild-
type meningococci (5/16 [31%] vs. 157/236 (67%); P=0.006;
Figure 6) and had higher platelet counts (P=0.005). Rash was
strongly related with lower platelet counts (P,0.0001). To
investigate the possibility that the clinical differences found
between the two patient groups were confounded by the different
ages of the patient groups, a multivariate analysis adjusting for age
was performed. The difference in platelet count (P=0.003) and
rash (P=0.004) remained statistically significant after adjusting for
age. Subgroup analysis of clonal complex 41/44 showed similar
results. The differences in platelet count (P=0.007), rash
(P=0.006), and age (P=0.053) between patients infected by
mutant and wild-type strains were also present in the subgroup of
clonal complex 41/44.
None of the patients infected with lpxL1 mutant strains
developed septic shock during clinical course, while 13% of the
wild-type-infected patients did. One patient infected with an lpxL1
mutant strain died of respiratory failure after multiple seizures. By
contrast, sepsis was the leading cause of death among patients
infected with wild-type meningococci (14 of 16 fatalities, 88%).
Thus, the lpxL1 mutation occurs frequently among meningo-
cocci causing meningitis. Patients infected by mutant strains have
a clinical phenotype consistent with less systemic inflammation
and reduced activation of the coagulant system.
Strain no. Isolated from serogroup ST Clonal complex Type of mutation in lpxL1
a
992008 CSF B 146 41/44 Not detected
aType of mutations found in lpxL1. Colors in parentheses correspond to colors shown in Figure 2. Type I mutation: insertion of IS1301 (pink), type II mutation: insertion
of IS1655 (pink), type III mutation: deletion of a guanine in a stretch of five guanines (yellow), type IV mutation: deletion of an adenosine in a stretch of five adenosines
(green), type V mutation: deletion or insertion of an adenosine in a stretch of seven adenosines (light and dark blue), type VI mutation: deletion of ten nucleotides (red),
type VII mutation: deletion of C-terminal part of the lpxL1 gene (gray). For all strains with conserved amino acid changes, the inactivation of lpxL1 has been confirmed
with analysis of the lipid A by mass spectrometry.
bNd: not determined.
cStrain 2020799 was part of both the panel of 114 isolates representing all major serogroups and clonal complexes and the panel of 254 isolates from patients in the
prospective cohort study.
doi:10.1371/journal.ppat.1000396.t001
Table 1. cont.
Figure 3. Comparison of IL-6 induction in MM-6 cells between wild-type strains and lpxL1 mutants. MM-6 cells were stimulated for 18 h
with titrations of indicated strains and IL-6 in supernatant was quantified with ELISA. H44/76 is a wild-type strain, L8 lpxL1 is a constructed lpxL1
mutant, pLAK33 is an LPS-deficient mutant, and all other strains are spontaneous lpxL1 mutants. Results of one representative experiment of three
independent experiments are shown. Error bars indicate S.E.M. of triplicates.
doi:10.1371/journal.ppat.1000396.g003
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Overall, we screened meningococcal isolates of 464 different
patients and identified 40 strains with an lpxL1 mutation. An
additional low-activity strain had no lpxL1 mutation but appeared
to be LPS-deficient; the responsible mutation is currently under
investigation. Thus, 8.6% of patients were infected with an lpxL1
mutant, which is surprisingly common. There are several lines of
evidence making it very likely that lpxL1 mutants arise spontane-
ously in the host instead of introduction of an lpxL1 mutation into
one or several clones and subsequent spreading among the
meningococcal population. Firstly, lpxL1 mutations exist in isolates
of many serogroups and clonal complexes. Secondly, we identified
12 unique mutations in lpxL1. Thirdly, most lpxL1 mutations
(71%) are due to frameshifts in homopolymeric nucleotide tracts,
making phase variation likely. Finally, we found evidence for
switching from wild-type to lpxL1 mutant in vivo in patients for
which multiple isolates were available.
A picture emerges of N. meningitidis modulating its lipid A
structure under selective pressure. Under some conditions, hexa-
acyl lipid A has to be beneficial to compensate for enhanced
recognition by the innate immune system. Lipid A with six acyl
chains can protect bacteria from the antibacterial molecules in
mucosal secretions, consistent with the observation that many
bacteria inhabiting the respiratory tract and gut still produce hexa-
acyl LPS [14]. Chronic inflammation of these environments due to
LPS stimulation is probably prevented because epithelial cells
express low levels of either TLR4, MD-2, or CD14 at the mucosal
surface. On the other hand, the submucosal spaces are normally
sterile and the defense cells present there, such as macrophages,
dendritic cells, and neutrophils, express all the components of the
LPS receptor complex and can therefore respond potently after an
encounter with a Gram-negative bacterium [14]. Perhaps for this
reason most species of Gram-negative bacteria with hexa-acyl lipid
A that inhabit the mucosal surfaces rarely become invasive. On the
other hand, many Gram-negative pathogens that cause systemic
infection do not produce hexa-acyl lipid A. Most of these bacteria
have other habitats than the mucosa and enter the body via
nonmucosal routes [6]. A good example is the plague bacillus
Yersinia pestis. At mammalian body temperature Y. pestis normally
produces tetra-acyl LPS that is poorly recognized by TLR4.
Interestingly, a modified strain that produced hexa-acyl LPS at
37uC was no longer virulent in wild-type mice but fully virulent in
TLR4-deficient mice, demonstrating the importance of evasion of
TLR4 activation for this bacterium [15]. N. meningitidis seems to be
one of the exceptions to the general rule that Gram-negative
bacteria with hexa-acyl lipid A do not cause systemic disease.
However, our observation that a proportion of clinical isolates
have penta-acylated LPS suggests that evasion of TLR4 activation
might aid the bacterium to circumvent host defences after crossing
the nasopharyngeal epithelium. The hypothesis that TLR4 plays
an important role in the prevention of meningococcal disease
corroborates with the finding that subjects with rare TLR4
mutations have an increased risk for developing the disease [16]. If
the assumption is correct that hexa-acyl LPS gives the bacterium
an advantage on mucosal surfaces and that non hexa-acyl LPS is
better for bacteria in submucosal spaces, one would expect that the
frequency of lpxL1 mutants is lower in meningococcal isolates from
the respiratory tract compared to meningococcal isolates from the
cerebrospinal fluid or blood.
Mogensen et al. showed that strain HF13 is specifically defective
in activation of the MyD88-independent pathway, but not in
inducing the MyD88-dependent pathway [11]. However, we
demonstrate that strain HF13 and other lpxL1 mutants are also
defective in inducing the MyD88-dependent cytokines IL-6, TNF-
a, and IL-1b. Our experiments indicate that lpxL1 mutants or
purified lpxL1 LPS compared to wild-type controls are not
specifically deficient in inducing the MyD88-dependent vs.
independent pathway. This apparent discrepancy might be
explained by the dose of bacteria used. If cells are stimulated
with a high dose of bacteria the difference between lpxL1 mutant
and wild-type is only detectable for the MyD88-independent
pathway. This is because LPS is the only bacterial component
capable of inducing the MyD88-independent pathway, while
Figure 4. Comparison between wild-type strains and lpxL1 mutants of IL-8 induction in HEK293 cells transfected with human TLR4.
HEK293 cells transfected with human TLR4, CD14, and MD-2 were stimulated for 18 h with titrations of indicated strains and IL-8 in supernatant was
quantified with ELISA. H44/76 is a wild-type strain, L8 lpxL1 is a constructed lpxL1 mutant, pLAK33 is an LPS-deficient mutant, and all other strains are
spontaneous lpxL1 mutants. Results of one representative experiment of three independent experiments are shown. Error bars indicate S.E.M. of
triplicates.
doi:10.1371/journal.ppat.1000396.g004
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dependent pathway (e.g. TLR2 ligands). When cells are stimulated
with lower doses of bacteria the difference in induction of the
MyD88-dependent pathway becomes apparent, because LPS is by
far the most active component of the bacterium and the other non-
TLR4 ligands that can activate the MyD88-dependent pathway
are diluted too far to be still active.
The relatively high frequency of phase variation raises the
question whether the lpxL1 mutations might have arisen in vitro
after isolation from the patient. Previously, we have performed
extensive research on the phase variation of porA in N. meningitidis.
In this gene, homopolymeric nucleotide tracts are found in the
promoter (polyguanidine) and in the coding region (polyadenine).
The frequencies by which these sequences vary in length are 10
23
[17,18]. Others showed phase variation of capsule expression
caused by insertion of IS1301 in the siaA gene with a frequency of
phase variation of 9610
24 [19,20]. In vitro selection of porA phase
variants and siaA phase variants have not been reported.
Meningococcal isolates received by the Netherlands Reference
Laboratory for Bacterial Meningitis (NRLBM) are low passages
(up to 2 passages). We sequenced the lpxL1 gene of 20 individual
colonies of a culture of a mutant isolate (971859 I) and of 25
individual colonies of a culture of isolate 971859 III and found in
each instance the same sequence, i.e. 20 mutant sequences and 25
wild-type sequences, respectively. Therefore, we estimate the
frequency of phase switching to be less than 2.2610
22.I n
addition, we sequenced lpxL1 of DNA extracted from a swap taken
from 4 different quadrants of another culture plate of isolate
971859 III. All 4 lpxL1 sequences were homogeneous and
identical. Thus we are confident that the discovered lpxL1
mutations are not caused by in vitro phase variation.
Infection with lpxL1-mutant meningococcal strains is associated
with a particular clinical phenotype, which consisted of less
systemic inflammation and reduced activation of the coagulant
system, reflected in less fever, higher serum platelet counts, and
lower numbers with rash. Moreover, our in vitro data have shown
that lpxL1 mutants induce much less pro-inflammatory cytokines
than wild-type strains. The coagulation system is activated through
upregulation of tissue factor [1]. It has been demonstrated that
LPS upregulates tissue factor on monocytes and endothelial cells
Table 2. Clinical features of 254 adults with meningococcal meningitis due to lpxL1 mutant and wild-type strains.
Characteristic Wild-type (N=237) lpxL1 mutant
e (N=17) P-value
f
Admission
Age in yr - median (IQR
a) 31 (19–51) 21 (19–30) 0.053
Fever (temperature .38.0uC) – no. (%) 87/231 (38) 2/16 (13) 0.057
Neck stiffness – no. (%) 205/234 (88) 17/17 (100) 0.23
Median score on GCS
b (IQR) 13 (10–15) 12 (11–15) 0.97
Rash 157/236 (67) 5/16 (31) 0.006
Hypotension (Systolic BP
c ,90 mmHg) – no. (%) 23/204 (11) 0/16 (0) 0.39
Focal neurological deficits – no. (%) 51/237 (22) 2/17 (12) 0.54
Laboratory investigations
Cerebrospinal fluid white cell count – median per mm
3 (IQR) 5205 (1466–12605) 5376 (3063–11416) 0.89
Positive blood culture – no. (%) 117/207 (49) 11/16 (69) 0.44
Platelet count – median 10
9/L (IQR) 162 (123–211) 215 (169–270) 0.005
Serum creatinine – median mmol/L (IQR) 95 (77–128) 84 (69–99) 0.051
Clinical course
Septic shock – no. (%)
d 30/237 (13) 0/17 (0) 0.23
Neurologic complication – no. (%) 98/237 (41) 5/17 (29) 0.45
Outcome
Death – no. (%) 18/237 (8) 1/17 (6) 1.00
Focal neurological deficits – no. (%) 25/218 (11) 3/16 (19) 0.42
Unfavourable outcome – no. (%) 27/237 (11) 3/17 (18) 0.43
aIQR denotes interquartile range.
bGCS Glasgow Coma Scale.
cBP blood pressure.
dSeptic shock was defined as systolic blood pressure ,90 mmHg with positive blood culture. Systolic blood pressure was measured on admission in 243 patients, GCS
in 253 patients, CSF white cell count in 238 patients, and serum platelet count in 241 patients.
eIn 16 strains a mutation in lpxL1 was found, but not in strain 992008.
fThe Mann-Whitney U test was used to identify differences between groups in continuous variables, and dichotomous variables were compared by the chi-square or
Fisher exact test.
doi:10.1371/journal.ppat.1000396.t002
Figure 5. Comparison between wild-type strains and lpxL1 mutants in pro-inflammatory cytokine induction in PBMCs. PBMCs from
three different donors were stimulated with titrations of the indicated strains and IL-6, TNF-a, and IL-1b were quantified in the supernatant 18 h after
stimulation. H44/76 is a wild-type strain, L8 lpxL1 is a constructed lpxL1 mutant, pLAK33 is an LPS-deficient mutant, and all other strains are
spontaneous lpxL1 mutants. Results of one representative experiment of two independent experiments are shown. Error bars indicate S.E.M. of
triplicates.
doi:10.1371/journal.ppat.1000396.g005
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kine IL-6 appears to mediate in vivo expression of tissue factor
[24,25]. Finally, IL-1b and TNF-a inhibit anticoagulant pathways
by downregulating thrombomodulin at the endothelial surface and
by increasing plasminogen activator inhibitor type-1 (PAI-1)
[26,27]. Thus, our finding that patients infected with an lpxL1
mutant show less activation of the coagulation system is consistent
with our results that show that lpxL1 LPS is less potent and that
lpxL1 mutants induce less pro-inflammatory cytokines.
Remarkably, the lpxL1 mutants induced the same degree of CSF
leukocytosis as wild-type strains. There are several explanations for
‘‘normal’’ CSF white cell counts in patients infected by mutant
strains. Patients in the cohort all had positive CSF cultures; almost
all had clinical signs of meningitis and CSF leukocytosis. Likely,
leukocytosis is not only mediated by lipid A, but also by other
microbial constituents.
It should be noted that not all groups of patients were included in
our analysis of clinical patient data. The study only included adults
with meningitis. Patients younger than 16 years or patients with sepsis
only were not included. Therefore, our results are potentially biased
by excluding these patient groups. Patients with meningitis often have
a less severe form of the disease, as reflected by the overall low
mortality of 8% in our study. However, patients with sepsis have very
serious symptoms resulting from high concentrations of bacteria in
the circulation. Mortality rates in these patients can be as high as
50%. Also, patients younger than 16 years are an import group,
because rates for meningococcal disease are highest for young
children [1]. It would be interesting to see whether lpxL1 mutants also
exist in these patients groups, and if so, if these patients have a
different clinical course compared to patients infected with a wild-
type strain. These additional data are needed to fully understand the
impact of lpxL1 mutations on meningococcal disease.
Meningococcal sepsis is generally seen as the prototypical
endotoxin-mediated disease. Here we report for the first time that
meningococcal lipid A mutants which are defective in TLR4
activation occur naturally. Their frequency is unexpectedly high,
suggesting an important role in virulence for the resulting low-
activity LPS. Our results suggest that inmost cases this mutation has
occurred through phase variation, and may give the bacteria an
advantage because they are less well sensed by the innate immune
system. Patients infected with these mutant strains endure milder
symptomswith lesssystemicinflammationandreduced activation of
the coagulant system, showing that our findings are clinically
relevant. Importantly, these results with lpxL1 also provide the first
example of a specific bacterial mutation which can be associated
with the clinical course of meningococcal disease. More generally, it
shows how there can be an underestimated heterogeneity in the
TLR4-activating capacity of pathogenic bacteria.
Materials and Methods
Ethics statement
This observational study with anonymous patient data was
carried out in accordance with the Dutch privacy legislation.
Written informed consent to use data made anonymous was
Figure 6. Clinical correlate of lpxL1 mutations in meningococcal
meningitis. (A) Frequency of rash in patients presenting with
meningitis infected by lpxL1 wild-type and mutant strains. (B,C) Platelet
counts on admission for lpxL1 wild-type and mutant strains (B) and
patients presenting with and without rash (C). Horizontal bars reflect
medians. The Mann-Whitney U test was used to identify differences
between groups in continuous variables, and dichotomous variables
were compared by the chi-square or Fisher exact test.
doi:10.1371/journal.ppat.1000396.g006
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representative.
N. meningitidis strains
Strain HF13 was a kind gift from M. Kilian. The constructed
lpxA and lpxL1 mutants were generated in the H44/76 strain as
previously described [8,9]. All other strains were selected from the
collection of the Netherlands Reference Laboratory for Bacterial
Meningitis. Details about year of isolation, serogroup, genotype
and anatomical site of isolation are presented in Table S1.
Meningococci were cultured in GC broth or on GC plates (Difco
laboratories) supplemented with 1% (vol/vol) Vitox (Oxoid) at
37uC in humified atmosphere of 5% CO2 [18]. Bacteria were
suspended in PBS and the A620 was determined. The bacteria
were heat inactivated at 56uC for 30 min. Serogrouping were
performed as described elsewhere [12]. MLST was performed as
described by Maiden et al [28].
Lipid A structure
Bacteria were grown as described above and suspended in
isobutyric acid-ammonium hydroxide 1 M (5:3, v/v). Lipid A was
extracted as described previously [29] with slight modifications.
The lipid A structure was analyzed by nanoelectrospray tandem
mass spectrometry (MS/MS) on a Finnigan LCQ in the negative
(MS) or positive (MS/MS) ion mode [30].
Sequencing
DNA was extracted from boiled cultures of N. meningitidis.
Sequencing of lpxL1 was carried out using primers 344-2 and 670-
1 (Table S2) and BigDyeTerminator chemistry (Applied Biosys-
tems) according to the instructions of the manufacturer. The
primers used to obtain sequences upstream and downstream of
lpxL1 are presented in Table S2. Sequence traces were obtained
with ABI Big-dyes and an ABI 3730 sequencer.
Cell lines and PBMCs
PBMC from HLA-oligotyped donors after leukapheresis were
isolated by centrifugation of buffy coat cells on Ficoll-Hypaque
(Pfizer) and were used after cryopreservation. For experiments
and/or maintenance, the human monocyte cell line Mono-mac-6
(MM6), the mouse macrophage cell line J774A.1, and PBMCs
were suspended in IMDM (Gibco BRL) supplemented with 100
units/ml penicillin, 100 mg/ml streptomycin, 300 mg/ml l-gluta-
mine (Gibco BRL), and 10% heat-inactivated fetal calf serum
(FCS) (Gibco BRL). For experiments and maintenance of HEK-
293 cells stably transfected with human TLR4A, MD-2, and
CD14 (Invivogen), DMEM (Gibco BRL) was used, supplemented
with 10% FCS, 10 mg/ml blasticidin (Invivogen), and 50 mg/ml
Hygromycin B (Invivogen).
ELISA
Depending on the experiment either J774A.1, MM6, PBMCs,
or HEK-293 hTLR4/MD-2/CD14 cells were used. Different
plates and quantities of cells were used: 1.10
6 cells in 1 ml medium
per well in 12-well plates, 9.10
4–5.10
5 cells in 250–1000 ml
medium per well in 24-well plates, and 1.10
5–3.10
5 cells in 200–
300 ml medium per well in 96-well plates. Cells were stimulated
with bacteria and incubated o/n at 37uC in a humidified
atmosphere containing 5% CO2. Cytokine concentrations in the
culture supernatants were quantified with ELISA. Mouse IP-10
was determined with mouse IP-10 ELISA kit (R&D systems) and
human IL-6, TNF-a, IL-1b, and IL-8 with PeliPairTM reagent
sets (Sanquin).
Meningitis cohort study
The Dutch Meningitis Cohort Study included 258 patients with
meningococcal meningitis; from 254 patients the bacterial strain
was stored in the Netherlands Reference Laboratory for Bacterial
Meningitis [13]. Inclusion and exclusion criteria have been
described extensively elsewhere [12]. In summary, eligible patients
were older than 16 years, had bacterial meningitis confirmed by
culture of cerebrospinal fluid (CSF), and were listed in the
database of the Netherlands Reference Laboratory for Bacterial
Meningitis from October 1998 to April 2002. This laboratory
receives CSF isolates from about 85% of all patients with bacterial
meningitis in the Netherlands. The treating physician was
contacted, and informed consent was obtained from all partici-
pating patients or their legally authorized representatives. This
observational study with anonymous patient data was carried out
in accordance with the Dutch privacy legislation. Patients
underwent a neurologic examination at discharge, and outcome
was graded with the Glasgow Outcome Scale. This measurement
scale is well validated with scores varying from 1 (indicating death)
to 5 (good recovery). A favourable outcome was defined as a score
of 5, and an unfavourable outcome as a score of 1–4. Focal
neurologic deficits were defined as focal cerebral deficits (aphasia,
monoparesis, or hemiparesis) or cranial nerve palsies. Serogroup-
ing, MLST, and susceptibility testing of meningococcal isolates
were performed by the Netherlands Reference Laboratory for
Bacterial Meningitis.
Statistics
The Mann-Whitney U test was used to identify differences
between groups in continuous variables, and dichotomous
variables were compared by the chi-square or Fisher exact test.
All statistical tests were 2-tailed, and a p value less than 0.05 was
regarded as significant.
List of accession numbers/ID numbers for genes
mentioned in the text
Please see Table S3 for accession numbers.
Supporting Information
Figure S1 Screening of N. meningitidis group Y clinical isolates on
cytokine induction. J774A.1 cells were stimulated for 3 h with a
panel of group Y strains (0.1 OD) and IP-10 in the supernatant
was determined with ELISA.
Found at: doi:10.1371/journal.ppat.1000396.s001 (2.74 MB TIF)
Figure S2 Screening of panel of N. meningitidis clinical isolates
representing all major serogroups and clonal complexes. MM6
cells were stimulated for 18 h with a selection of clinical isolates
(0.001 OD) representing all serogroups and clonal complexes. IL-6
was determined in the supernatant with ELISA.
Found at: doi:10.1371/journal.ppat.1000396.s002 (4.22 MB TIF)
Figure S3 Screening of panel of multiple isolates per patient.
MM6 cells were stimulated for 18 h with a panel of clinical isolates
(0.001 OD), of which multiple isolates were obtained from a single
patient. IL-6 was determined with ELISA.
Found at: doi:10.1371/journal.ppat.1000396.s003 (4.43 MB TIF)
Figure S4 Screening of clinical isolates of patients included in
the Dutch meningitis cohort study. MM6 cells were stimulated for
18 h with 254 isolates from patients with meningitis (0.001 OD).
IL-6 was determined with ELISA.
Found at: doi:10.1371/journal.ppat.1000396.s004 (7.22 MB TIF)
Table S1 List of meningococcal strains used in this study.
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Table S2 List of primers used for the sequencing of lpxL1.
Found at: doi:10.1371/journal.ppat.1000396.s006 (0.03 MB
DOC)
Table S3 List of accession numbers/ID numbers for genes
mentioned in the text.
Found at: doi:10.1371/journal.ppat.1000396.s007 (0.06 MB
DOC)
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